Dr amy prawira

Conjoint Lecturer
Medicine & Health
School of Clinical Medicine
  • Journal articles | 2026
    Lin FP; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Desai J; Zaheed M; Chinchen S; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Mersiades A; Millward M; Brown MP; Charakidis M; Pokorny AMJ; Craft P; Espinoza D; Grimison P; Harrup R; Joshua AM; O'byrne K; Lee CK; Cowley MJ; Ballinger ML; Simes J; Thomas DM, 2026, 'Genomic Therapy Matching in Rare and Refractory Cancers', JAMA Oncology, 12, pp. 458 - 467, http://dx.doi.org/10.1001/jamaoncol.2026.0127
    Journal articles | 2025
    Atkinson VG; Brenner W; Brown JT; Cabezón-Gutiérrez L; Gajate P; Kim ST; Lee J; Lemech C; Margolin KA; Moreno I; Moreno V; Oh D-Y; Oliva IG; Park JJ; Shue H; Twardowski P; Winer I; Chisamore MJ; Prawira A; Merchant F; Coello M; To MD; Merchant R; Yavari A; Ascierto PA, 2025, 'Abstract CT047: Interim results from the phase 1/2 ABILITY-1 study of a long-acting ‘beta-enhanced not-alpha’ IL-2 superkine in patients with advanced solid tumors', Cancer Research, 85, pp. ct047 - ct047, http://dx.doi.org/10.1158/1538-7445.am2025-ct047
    Journal articles | 2025
    Mansinho AB; Atkinson VG; Borau PG; Gutierrez LC; Carbo CH; Coelho SMCP; Candilejo IM; Chisamore MJ; Prawira A; Merchant F; Coello M; To MD; Yavari A; Merchant R; Ascierto PA, 2025, '250P ABILITY-1, a phase I/II study of MDNA11, a next generation IL-2 agonist, alone or with pembrolizumab in advanced solid tumors: Interim analysis', Immuno-Oncology Technology, 28, pp. 101449, http://dx.doi.org/10.1016/j.iotech.2025.101449
    Journal articles | 2025
    Panda PK; Ting FIL; Shimizu T; Day D; Prasongsook N; Hui MN; Heong VYM; Tan A; Prawira A; Voon P-J; Thambamroong T; Park S; El-Helali A; Tan DS; Koyama T; Tran B; Ueno NT; Tan DSW; Loong HHF; Tan TJY, 2025, '88O Improving access to clinical trials and novel therapeutics for advanced solid tumours in the Asia-Pacific Region: Insights from the ASTER study', ESMO Open, 10, pp. 105439, http://dx.doi.org/10.1016/j.esmoop.2025.105439
    Journal articles | 2024
    Atkinson VG; Antras JF; Bedard P; Brenner W; Brown J; Lemech CR; Lloyd P; Margolin K; Mathew M; Park JJ; Thomas S; Twardowski P; Gardner H; Prawira A; Coello M; Ebrahimimizadeh W; To MD; Merchant R; Karanam SM; Yavari A; Siu LL; Tawbi HA; Ascierto PA, 2024, 'Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors', Cancer Research, 84, pp. ct259 - ct259, http://dx.doi.org/10.1158/1538-7445.am2024-ct259
    Journal articles | 2024
    Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN, 2024, 'Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study', Cancer, 130, pp. 1991 - 2002, http://dx.doi.org/10.1002/cncr.35226
    Journal articles | 2023
    Day D; Park JJ; Coward J; Markman B; Lemech C; Kuo JC; Prawira A; Brown MP; Bishnoi S; Kotasek D; Strother RM; Cosman R; Su R; Ma Y; Yue Z; Hu HH; Wu R; Li P; Tse AN, 2023, 'A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer', British Journal of Cancer, 129, pp. 1608 - 1618, http://dx.doi.org/10.1038/s41416-023-02431-7
    Journal articles | 2023
    Hernando-Calvo A; Malone E; Day D; Prawira A; Weinreb I; Yang SYC; Wong H; Rodriguez A; Jennings S; Eliason A; Wang L; Spreafico A; Siu LL; Hansen AR, 2023, 'Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial', Cancer Medicine, 12, pp. 20299 - 20310, http://dx.doi.org/10.1002/cam4.6589
    Journal articles | 2023
    Lim J; Akbar Ali S; Prawira A; Sim HW, 2023, 'Impact of travel distance on outcomes for clinical trial patients: the Kinghorn Cancer Centre experience', Internal Medicine Journal, 53, pp. 242 - 249, http://dx.doi.org/10.1111/imj.15561
    Journal articles | 2023
    Loong HH; Shimizu T; Prawira A; Tan AC; Tran B; Day D; Tan DSP; Ting FIL; Chiu JW; Hui M; Wilson MK; Prasongsook N; Koyama T; Reungwetwattana T; Tan TJ; Heong V; Voon PJ; Park S; Tan IB; Chan SL; Tan DSW, 2023, 'Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group', ESMO Open, 8, http://dx.doi.org/10.1016/j.esmoop.2023.101586
    Journal articles | 2022
    Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ, 2022, 'Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: Interim results from a multicenter phase I/II trial', Journal for Immunotherapy of Cancer, 10, http://dx.doi.org/10.1136/jitc-2021-004424
    Journal articles | 2022
    Schöffski P; Tan DSW; Martín M; Ochoa-De-Olza M; Sarantopoulos J; Carvajal RD; Kyi C; Esaki T; Prawira A; Akerley W; De Braud F; Hui R; Zhang T; Soo RA; Maur M; Weickhardt A; Krauss J; Deschler-Baier B; Lau A; Samant TS; Longmire T; Chowdhury NR; Sabatos-Peyton CA; Patel N; Ramesh R; Hu T; Carion A; Gusenleitner D; Yerramilli-Rao P; Askoxylakis V; Kwak EL; Hong DS, 2022, 'Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies', Journal for Immunotherapy of Cancer, 10, http://dx.doi.org/10.1136/jitc-2021-003776
    Journal articles | 2021
    Oliva M; Chepeha D; Araujo DV; Diaz-Mejia JJ; Olson P; Prawira A; Spreafico A; Bratman SV; Shek T; De Almeida J; R Hansen A; Hope A; Goldstein D; Weinreb I; Smith S; Perez-Ordoñez B; Irish J; Torti D; Bruce JP; Wang BX; Fortuna A; Pugh TJ; Der-Torossian H; Shazer R; Attanasio N; Au Q; Tin A; Feeney J; Sethi H; Aleshin A; Chen I; Siu L, 2021, 'Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study', Journal for Immunotherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2021-003476
    Journal articles | 2021
    Sachdev JC; Prawira A; Chaudhry A; Ganju V; Trudeau C; Scott J; Woloski R; Paoloni M; Zhang H; Gardner O, 2021, 'Abstract PS12-12: Efficacy and safety of AB928 plus pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with metastatic ovarian and triple negative breast cancer', Cancer Research, 81, pp. ps12-12-ps12-12, http://dx.doi.org/10.1158/1538-7445.sabcs20-ps12-12
    Journal articles | 2020
    Bendell JC; Bedard P; Bang Y-J; LoRusso P; Hodi S; Gordon M; D'Angelo S; D'Angelo S; Desai J; Garralda E; Italiano A; Ahn M-J; Cervantes A; Wainberg Z; Calvo E; Gil-Martin M; Martinez-Garcia M; Bahleda R; Cassier P; Delord J-P; Prawira A; Melero I; Emens L; Romano E; Miller K; Hsieh RW; Xue C; Morrissey K; Twomey P; Gash K; Patil NS; Grogan J; Meng R; Cho B; Kim TW, 2020, 'Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors', Cancer Research, 80, pp. ct302 - ct302, http://dx.doi.org/10.1158/1538-7445.am2020-ct302
    Journal articles | 2020
    Day D; Prawira A; Spreafico A; Waldron J; Karithanam R; Giuliani M; Weinreb I; Kim J; Cho J; Hope A; Bayley A; Ringash J; Bratman SV; Jang R; O'Sullivan B; Siu LL; Hansen AR, 2020, 'Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck', Oral Oncology, 108, http://dx.doi.org/10.1016/j.oraloncology.2020.104753
    Journal articles | 2020
    Gallagher RM; Pattatheyil A; Pantvaidya GH; Panizza BJ; Sharan R; Deshmukh AD; Barnett CME; Swart DJ; Mynott TL; Cleal A; Gordon V; Prawira A, 2020, 'Exploratory phase Ib/IIa study of intratumorally administered tigilanol tiglate to assess safety, tolerability and tumour response in patients with head and neck squamous cell carcinoma', Annals of Oncology, 31, pp. s684, http://dx.doi.org/10.1016/j.annonc.2020.08.1089
    Journal articles | 2020
    Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073
    Journal articles | 2020
    Millward M; Frentzas S; Gan HK; Prawira A; Tran B; Coward J; Jin X; Li B; Wang M; Kwek KY; Xia Y; Desai J, 2020, 'Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies', Annals of Oncology, 31, pp. s705 - s706, http://dx.doi.org/10.1016/j.annonc.2020.08.1141
    Journal articles | 2020
    Mislang ARA; Coward J; Cooper A; Underhill CR; Zheng Y; Xu N; Xiao C; Jin X; Li B; Wang M; Kwek KY; Xia D; Xia Y; Prawira A, 2020, '157P Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers', Annals of Oncology, 31, pp. s1300 - s1301, http://dx.doi.org/10.1016/j.annonc.2020.10.178
    Journal articles | 2020
    Oliva Bernal M; Araujo DV; Chepeha DB; Prawira A; Spreafico A; Bratman SV; Shek T; de Almeida JR; Hansen AR; Hope AJ; Goldstein DP; Weinreb I; Perez-Ordonez B; Pugh TJ; Ohashi PS; Wang BX; Irish JC; Der-Torossian H; Chen I; Siu LL, 2020, 'SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study.', Journal of Clinical Oncology, 38, pp. 6569 - 6569, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6569
    Journal articles | 2020
    Prawira A; Coward J; Mislang A; Nagrial A; Gan H; Jin X; Li B; Wang ZM; Kwek KY; Xia D; Xia Y, 2020, '384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas', Journal for ImmunoTherapy of Cancer, 8, pp. a233 - a233, http://dx.doi.org/10.1136/jitc-2020-sitc2020.0384
    Journal articles | 2019
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM, 2019, 'Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', Oncologist, 24, pp. 1188 - 1194, http://dx.doi.org/10.1634/theoncologist.2018-0621
    Journal articles | 2019
    Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; De Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B, 2019, 'Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer', BMC Cancer, 19, http://dx.doi.org/10.1186/s12885-019-5380-3
    Journal articles | 2019
    Stradella A; Johnson ML; Goel S; Chandana SR; Galsky MD; Calvo E; Moreno V; Park H; Arkenau H-T; Cervantes A; Madrid LF; Mileshkin L; Plummer R; Evans J; Horvath L; Prawira A; Pelham RJ; Mu S; Andreu-Vieyra C; Barve M, 2019, '451PD Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours', Annals of Oncology, 30, pp. v166 - v167, http://dx.doi.org/10.1093/annonc/mdz244.013
    Journal articles | 2018
    Hong DS; Schoffski P; Calvo A; Sarantopoulos J; Ochoa De Olza M; Carvajal RD; Prawira A; Kyi C; Esaki T; Akerley WL; De Braud FG; Hui R; Zhang T; Soo RA; Maur M; Weickhardt AJ; Roy Chowdhury N; Sabatos-Peyton C; Kwak EL; Tan DS-W, 2018, 'Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.', Journal of Clinical Oncology, 36, pp. 3012 - 3012, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.3012
    Journal articles | 2017
    George M; Mandaliya H; prawira A, 2017, 'A survey of medical oncology training in Australian Medical Schools: pilot study', JMIR Medical Education, 12, pp. e23 - e23, http://dx.doi.org/10.2196/mededu.7903
    Journal articles | 2017
    Infante JR; Bedard PL; Shapiro G; Bauer TM; Prawira A; Laskin O; Weetall M; Baird J; Branstrom A; O'Mara E; Spiegel RJ, 2017, 'Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.', Journal of Clinical Oncology, 35, pp. 2574 - 2574, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2574
    Journal articles | 2017
    Prawira A; Lazinski D; Siu LL; Perez-Ordonez B, 2017, 'Giant Prolactinoma Presenting As a Base of Skull Tumor With Nasopharyngeal Extension: A Potential Diagnostic Pitfall in Neuroendocrine Lesions of the Base of Skull', Head and Neck Pathology, 11, pp. 537 - 540, http://dx.doi.org/10.1007/s12105-017-0782-5
    Journal articles | 2017
    Prawira A; Oosting SF; Chen TW; Delos Santos KA; Saluja R; Wang L; Siu LL; Chan KKW; Hansen AR, 2017, 'Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review', British Journal of Cancer, 117, pp. 1743 - 1752, http://dx.doi.org/10.1038/bjc.2017.357
    Journal articles | 2017
    Prawira A; Pugh TJ; Stockley TL; Siu LL, 2017, 'Data resources for the identification and interpretation of actionable mutations by clinicians', Annals of Oncology Official Journal of the European Society for Medical Oncology, 28, pp. 946 - 957, http://dx.doi.org/10.1093/annonc/mdx023
    Journal articles | 2017
    Prawira A; Stundzia AB; Dufort P; Halankar J; Paravasthu DM; Spreafico A; Hansen AR; Razak ARA; Bedard PL; Butler M; Lheureux S; Oza AM; Jang RW; Suta KM; Boross-Harmer S; Cipollone J; Chow H; Metser U; Siu LL, 2017, '115P Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs)', Annals of Oncology, 28, pp. v31, http://dx.doi.org/10.1093/annonc/mdx363.031
    Journal articles | 2017
    Wong H-L; Luechtefeld T; Prawira A; Patterson Z; Workman J; Day D; Chooback N; Nappi L; Samawi HH; Lavoie J-M; Spreafico A; Hansen AR; Sahebjam S; Siu LL; Ivy SP; Paller C; Renouf D, 2017, '1468P Development of a web-based application using machine learning algorithms to facilitate systematic literature reviews', Annals of Oncology, 28, pp. v518, http://dx.doi.org/10.1093/annonc/mdx385.023
    Journal articles | 2016
    Mehnert JM; Varga A; Brose M; Aggarwal RR; Lin C-C; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B, 2016, 'Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study.', Journal of Clinical Oncology, 34, pp. 6091 - 6091, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.6091
    Journal articles | 2016
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak ARA; Chen EX; Jang R; O’Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR, 2016, 'Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)', Investigational New Drugs, 34, pp. 575 - 583, http://dx.doi.org/10.1007/s10637-016-0367-2
    Journal articles | 2016
    Prawira A; Dufort P; Halankar J; Paravasthu DM; Hansen A; Spreafico A; Razak ARA; Chen E; Jang RW; Metser U; Siu LL, 2016, 'Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)', Annals of Oncology, 27, pp. vi330, http://dx.doi.org/10.1093/annonc/mdw376.08
    Journal articles | 2016
    Prawira A; Oosting S; Chen TW-W; Saluja R; Delos Santos K; Wang L; Siu LL; Chan KK; Hansen AR, 2016, 'Systemic therapies for recurrent/metastatic nasopharyngeal carcinoma (RM NPC).', Journal of Clinical Oncology, 34, pp. 6031 - 6031, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.6031
    Journal articles | 2016
    Shapiro G; Bedard P; Infante J; Bauer T; Prawira A; Laksin O; Weetall M; Baird J; Branstrom A; O'Mara E; Spiegel R, 2016, '452 Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein', European Journal of Cancer, 69, pp. s148, http://dx.doi.org/10.1016/s0959-8049(16)33039-8
    Journal articles | 2016
    Shapiro G; Infante J; Bauer TM; Prawira A; Bedard P; Laskin O; Weetall M; Baird J; O'Mara E; Spiegel R, 2016, 'Initial first-in-human phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levels', Annals of Oncology, 27, pp. vi122, http://dx.doi.org/10.1093/annonc/mdw368.27
    Journal articles | 2015
    Mandaliya H; Baghi P; Prawira A; George MK, 2015, 'A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis', Case Reports in Oncological Medicine, 2015, pp. 825603, http://dx.doi.org/10.1155/2015/825603
    Journal articles | 2014
    George M; Ngo P; Prawira A, 2014, 'Rural oncology: Overcoming the tyranny of distance for improved cancer care', Journal of Oncology Practice, 10, pp. e146 - e149, http://dx.doi.org/10.1200/JOP.2013.001228
    Journal articles | 2009
    Wong MLH; Prawira A; Kaye AH; Hovens CM, 2009, 'Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas', Journal of Clinical Neuroscience, 16, pp. 1119 - 1130, http://dx.doi.org/10.1016/j.jocn.2009.02.009
  • Conference Papers | 2026
    Mansinho A; Atkinson V; L Bedard P; Gajate P; T Brown J; Cabezón-Gutiérrez L; Duffy A; Moreno V; A Margolin K; Twardowski P; Moreno I; Shue H; Winer I; J Chisamore M; Oliva M; Prawira A; Merchant F; Merchant R; D Gwynne W; D To M; Ibrahim N; Yavari A; Coello M; A Tawbi H; Coelho S; Medic I; Hernandez-Guerrero T; A Ascierto P, 2026, '517 MDNA11 demonstrates clinical activity as monotherapy and in combination with pembrolizumab in biomarker-enriched gastrointestinal malignancies, including ICI-refractory disease', BMJ, pp. a578 - a578, presented at Regular Abstracts, http://dx.doi.org/10.1136/jitc-2026-sitc2026.0517
    Conference Papers | 2023
    To MD; Merchant R; Atkinson V; Bedard P; Brenner W; Coello M; Antras JF; Galligan C; Lemech C; Lloyd P; Karanam SM; Margolin K; Mathew M; Prawira A; Thomas S; Twardowski P; Yavari A; Merchant F, 2023, '760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors', BMJ, pp. a856 - a856, presented at Regular and Young Investigator Award Abstracts, http://dx.doi.org/10.1136/jitc-2023-sitc2023.0760
    Conference Abstracts | 2022
    , 2022, 'Poster Abstracts', in Asia-Pacific Journal of Clinical Oncology, Wiley, Vol. 18, pp. 33 - 51, http://dx.doi.org/10.1111/ajco.13856
    Conference Papers | 2021
    Hernando-Calvo A; Malone E; Dai D; Prawira A; Weinreb I; Eliason A; Rodriguez A; Lajkosz K; Jennings S; Spreafico A; Siu LL; Hansen A, 2021, 'Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. p154 - p154, http://dx.doi.org/10.1158/1535-7163.targ-21-p154
    Conference Papers | 2021
    Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SR; Smyth LM; Hamilton EP, 2021, 'Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer', in Cancer Research, American Association for Cancer Research (AACR), pp. ot-09-03-ot-09-03, http://dx.doi.org/10.1158/1538-7445.sabcs20-ot-09-03
    Conference Abstracts | 2020
    Markman B; Day D; Park JJW; Coward J; Bishnoi S; Kotasek D; Eek R; Brown MP; Lemech C; Kuo J; Prawira A; Strother R; Zhang Q; Wang L; Chen R; Ma Y; Qin Z; Tse A, 2020, 'Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing', in Annals of Oncology, Elsevier, Vol. 31, pp. s722, http://dx.doi.org/10.1016/j.annonc.2020.08.1177
    Conference Abstracts | 2020
    Stradella A; Johnson M; Goel S; Chandana SR; Galsky MD; Calvo E; Moreno V; Park H; Arkenau T; Cervantes A; Fariñas-Madrid L; Mileshkin L; Fu S; Plummer R; Evans J; Horvath L; Prawira A; Qu K; Pelham R; Barve MA, 2020, 'Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)', in Annals of Oncology, Elsevier, Vol. 31, pp. s465 - s466, http://dx.doi.org/10.1016/j.annonc.2020.08.644
    Conference Papers | 2019
    Bernal MO; Chepeha D; Prawira A; Vines D; Spreafico A; Bratman S; Almeida JD; Hansen A; Goldstein D; Gilbert R; Gullane P; Brown DH; Weinreb I; Perez-Ordoñez B; Ohashi PS; McGaha T; Wang BX; Irish J; Chen I; Siu LL, 2019, 'Abstract CT124: Sitravatinib and nivolumab in oral cavity cancer window of opportunity study (SNOW)', in Cancer Research, American Association for Cancer Research (AACR), pp. ct124 - ct124, http://dx.doi.org/10.1158/1538-7445.am2019-ct124
    Conference Papers | 2019
    Bernal MO; Chepeha D; Prawira A; Vines D; Spreafico A; Bratman S; Almeida JD; Hansen A; Goldstein D; Gilbert R; Gullane P; Brown DH; Weinreb I; Perez-Ordoñez B; Ohashi PS; McGaha T; Wang BX; Irish J; Chen I; Siu LL, 2019, 'Abstract CT124: Sitravatinib and nivolumab in oral cavity cancer window of opportunity study (SNOW)', American Association for Cancer Research (AACR), pp. ct124 - ct124, presented at Clinical Trials, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct124
    Conference Papers | 2019
    Kotasek D; Coward J; de Souza PL; Underhill C; Jin X; Li B; Xia Y; Prawira A, 2019, 'A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), pp. e14006 - e14006, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14006
    Conference Abstracts | 2019
    Millward M; Gan HK; Joshua AM; Kuo JC-Y; Prawira A; Richardson GE; Barbee SD; Inamdar SP; Pierce KL; Qureshi M; Horvath L, 2019, 'FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. tps42 - tps42, http://dx.doi.org/10.1200/jco.2019.37.8_suppl.tps42
    Conference Papers | 2018
    Xu K; Lo A; Chin V; Gzell C; O'Connor C; Forstner D; Gallagher R; Bova R; Crawford J; Harvey R; Lochhead A; Earls P; Qiu MR; Hsu E; Bigg-Wither G; Chan L; Bao H; Foltyn P; Sim HW; Prawira A, 2018, 'Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii389, http://dx.doi.org/10.1093/annonc/mdy287.049
    Conference Posters | 2016
    Hansen A; Tannock I; Templeton AJ; Prawira A; Knox J; Vera-Badillo F; Chen E; Zavitz MB; Wang L; Evans A; Tan Q; Wouters B; Sridhar S; Joshua A, 2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)', Vol. 27, pp. vi249, http://dx.doi.org/10.1093/annonc/mdw372.20
    Conference Posters | 2016
    Hansen AR; Tannock I; Prawira A; Knox JJ; Templeton AJ; Vera-Badillo F; Chen EX; Zavitz M-B; Wang L; Evans A; Tan S; Wouters B; Sridhar SS; Joshua AM, 2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC).', Vol. 34, pp. e16502 - e16502, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.e16502
    Preprints |
    George M; Mandaliya H; Prawira A, A Survey of Medical Oncology Training in Australian Medical Schools: Pilot Study (Preprint), http://dx.doi.org/10.2196/preprints.7903
    Preprints |
    Hernando-Calvo A; Malone E; Day D; Prawira A; Weinreb I; Wong H; Rodriguez A; Jennings S; Eliason A; Wang L; Spreafico A; Siu LL; Hansen A, Selinexor for the treatment of recurrent or metastatic salivary gland tumors: results from the GEMS-001 clinical trial., http://dx.doi.org/10.21203/rs.3.rs-2114261/v1